Hôpital Nord

Running trials

• Not yet recruiting

  Discontinuation Versus Continuation of Riociguat Monotherapy in Chronic Thromboembolic Pulmonary Hypertension Successfully Treated With Balloon Pulmonary Angioplasty

  NCT07644377· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  A Study of DS-3939a in Participants With Solid Tumors

  NCT07739966· Phase 1/2· Daiichi Sankyo· Source

• Not yet recruiting

  Short- and Mid-term Therapeutic, Prognostic, and Societal Impact of Implementing Intraoperative Assessment of Pulmonary Resection Quality for Lung Cancer

  NCT07828938· Fondation Hôpital Saint-Joseph· Source

• Recruiting

  A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT07499232· Phase 3· Janssen Research & Development, LLC· Source

• Not yet recruiting

  ActiTENS Mini (Transcutaneous Electrical Stimulation) in Women With Chronic Pain From Pelvic Endometriosis

  NCT07317037· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Tolerance of Local Administration of Cryopreserved Autologous Stromal Vascular Fraction Combined With Micrograft for the Treatment of Refractory Ano-perineal Fistulas in Crohn's Disease

  NCT07629245· Phase 1/2· Assistance Publique Hopitaux De Marseille· Source

• Recruiting

  Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

  NCT07185997· Phase 3· ArriVent BioPharma, Inc.· Source

• Recruiting

  Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer

  NCT07563205· GFPC Investigation· Source

• Recruiting

  Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

  NCT06745908· Phase 3· ImmunityBio, Inc.· Source

• Recruiting

  Study of Tissue Repair in Inflammatory Bowel Disease Exploiting Organoid Technology

  NCT06805890· Assistance Publique Hopitaux De Marseille· Source

• Recruiting

  Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)

  NCT07243132· GFPC Investigation· Source

• Recruiting

  Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib

  NCT06620835· Phase 2· Groupe Francais De Pneumo-Cancerologie· Source

• Recruiting

  Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

  NCT06472245· Phase 3· OSE Immunotherapeutics· Source

• Recruiting

  FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

  NCT06669117· Phase 1/2· Pierre Fabre Medicament· Source

• Recruiting

  National Registry of Surgical Treatment and Percutaneous Cryoablation of Parietal Endometriosis

  NCT06356831· Centre Hospitalier Intercommunal Creteil· Source

• Recruiting

  FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum

  NCT06393816· Phase 2· Centre Leon Berard· Source

• Active, not recruiting

  Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.

  NCT05930275· AbbVie· Source

• Recruiting

  Low Stable Pressure Pneumoperitoneum in Colorectal Surgery (CROSS STUDY)

  NCT06154785· Bordeaux Colorectal Institute Academy· Source

• Recruiting

  Evaluation of the Vivo Isar Stent System in Routine Clinical Practice

  NCT06420505· Translumina GmbH· Source

• Recruiting

  G-POEM for Refractory Gastroparesis After Esophagectomy With Gastric Pull-through

  NCT06068127· Institute for Clinical and Experimental Medicine· Source

• Recruiting

  A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

  NCT05967689· Phase 2· Taiho Oncology, Inc.· Source

• Recruiting

  Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock

  NCT04020263· Phase 3· Pr Bruno LEVY· Source

• Active, not recruiting

  An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)

  NCT05841537· AbbVie· Source

• Recruiting

  Impact of First-trimester Preeclampsia Screening on Perinatal and Maternal Morbidity (RANSPRE)

  NCT05521776· Assistance Publique - Hôpitaux de Paris· Source

• Active, not recruiting

  An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe

  NCT05363319· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice

  NCT05494606· AbbVie· Source

• Recruiting

  Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma

  NCT04749108· Phase 2/3· Institut du Cancer de Montpellier - Val d'Aurelle· Source

• Recruiting

  Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC

  NCT05122806· Groupe Francais De Pneumo-Cancerologie· Source

• Recruiting

  Molecular Signature From Tumor to Lymph Nodes

  NCT04677205· Assistance Publique - Hôpitaux de Paris· Source

• Active, not recruiting

  Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE)

  NCT05049044· Groupe Francais De Pneumo-Cancerologie· Source

• Active, not recruiting

  A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

  NCT03148418· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Nonfunctioning Small (≤2 cm) Neuroendocrine Pancreatic Incidentaloma

  NCT03022188· Société Française d'Endoscopie Digestive· Source

• Active, not recruiting

  Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

  NCT02568267· Phase 2· Hoffmann-La Roche· Source

• Active, not recruiting

  Biological and Clinical Database for Pancreatic Adenocarcinoma

  NCT02818829· University Hospital, Toulouse· Source

• Active, not recruiting

  Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Breast Cancer

  NCT02089100· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Enrolling by invitation

  Juvenile Inflammatory Rheumatism (JIR) Cohorte

  NCT02377245· Michaël Hofer· Source

• Active, not recruiting

  A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer

  NCT01957436· Phase 3· UNICANCER· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer12 recruiting
• Crohn's disease3 recruiting
• Colorectal cancer2 recruiting
• Coronary artery disease1 recruiting
• Endometriosis1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Gastroparesis1 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Rheumatoid arthritis1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  Multicentric Evaluation of the True Negative Predictive Value of Multiparametric MRI for the Detection of Prostate Cancer Using Cystoprostatectomy Specimen as Reference

  NCT03960112· Institut Paoli-Calmettes· Source

• Terminated

  CO2 Removal in Severe Acute exacerbatIons of Chronic Obstructive Lung Diseases

  NCT05546606· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)

  NCT05308966· Groupe Francais De Pneumo-Cancerologie· Source

• Completed

  Multicentric Prospective Study to Screen Inborn Errors of Metabolism in Non-immune Hydrops (NIH) Fetalis by Massively Parallel Sequencing

  NCT04308603· Hospices Civils de Lyon· Source

• Completed

  A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

  NCT04620330· Phase 2· Verastem, Inc.· Source

• Completed

  Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation

  NCT04233021· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source

• Terminated

  Assessment of Quitting Versus Using Aspirin Therapy In Patients Treated With Oral Anticoagulation for Atrial Fibrillation or Other Indication With Stabilized Coronary Artery Disease

  NCT04217447· Phase 3· University Hospital, Brest· Source

• Completed

  Registry of Asthma Patients Initiating DUPIXENT®

  NCT04287621· Regeneron Pharmaceuticals· Source

• Completed

  BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

  NCT03762018· Phase 3· ETOP IBCSG Partners Foundation· Source

• Completed

  Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

  NCT03829319· Phase 3· Merck Sharp & Dohme LLC· Source

• Terminated

  MR Imaging of Lung in the Follow-up Assessment of Cystic Fibrosis

  NCT03357562· University Hospital, Bordeaux· Source

• Completed

  Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

  NCT02914535· Phase 3· Alfasigma S.p.A.· Source

• Completed

  PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA

  NCT03006432· Phase 3· Federation Francophone de Cancerologie Digestive· Source

• Completed

  Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

  NCT02784171· Phase 2/3· Canadian Cancer Trials Group· Source

• Completed

  Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions

  NCT02738125· AbbVie· Source

• Completed

  Avelumab in First-line NSCLC (JAVELIN Lung 100)

  NCT02576574· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer

  NCT02359968· Phase 2· Centre Oscar Lambret· Source

• Completed

  SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

  NCT02117167· Phase 2· UNICANCER· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

  NCT02003924· Phase 3· Pfizer· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Lyme disease3 works · 0 trials
• Gastroparesis3 works · 1 trial